ONC-392,Pembrolizumab
biontech,Merck
['sclc', 'nsclc', '$bntx', 'biontech']
$bntx biontech and oncoc4 present positive phase 1/2 data for antibody candidate bnt316/onc-392 in hard-to-treat nsclc at asco #clinicaltrial#trading #investing 
Stay ahead of the market with ultra-fast stock news updates. 
FREE with 15 sec delay. Upgrade to Gold for even faster news & exclusive features @ https://t.co/LViEqnfZ7i